Volume 118, Issue 1 , Pages 53-61, July 2006
Prevention of asthma during the first 5 years of life: A randomized controlled trial
Background
Early life exposures may be important in the development of asthma and allergic disease.
Objective
To test house dust mite (HDM) avoidance and dietary fatty acid modification, implemented throughout the first 5 years of life, as interventions to prevent asthma and allergic disease.
Methods
We recruited newborns with a family history of asthma antenatally and randomized them, separately, to HDM avoidance or control and to dietary modification or control. At age 5 years, they were assessed for asthma and eczema and had skin prick tests for atopy.
Results
Of 616 children randomized, 516 (84%) were evaluated at age 5 years. The HDM avoidance intervention resulted in a 61% reduction in HDM allergen concentrations (μg/g dust) in the child's bed but no difference in the prevalence of asthma, wheeze, or atopy (P > .1). The prevalence of eczema was higher in the active HDM avoidance group (26% vs 19%; P = .06). The ratio of ω-6 to ω-3 fatty acids in plasma was lower in the active diet group (5.8 vs 7.4; P < .0001). However, the prevalence of asthma, wheezing, eczema, or atopy did not differ between the diet groups (P > .1).
Conclusion
Further research is required to establish whether other interventions can be recommended for the prevention of asthma and allergic disease.
Clinical implications
House dust mite avoidance measures and dietary fatty acid modification, as implemented in this trial during infancy and early childhood, did not prevent the onset of asthma, eczema, or atopy in high-risk children.
Key words: Allergen avoidance, ω-3 fatty acids, prevention, birth cohort, house dust mite
Abbreviation used: HDM, House dust mite
Supported by National Health and Medical Research Council of Australia, Cooperative Research Centre for Asthma, New South Wales Department of Health, Children's Hospital Westmead. Dr Almqvist was funded by the Swedish Heart Lung Foundation and Swedish Society of Medicine. Contributions of goods and services were made by Allergopharma Joachim Ganzer KG Germany, John Sands Australia, Hasbro, Toll Refrigerated, AstraZeneca Australia, and Nu-Mega Ingredients Pty Ltd. Goods were provided at reduced cost by Auspharm, Allersearch, and Goodman Fielder Foods.Disclosure of potential conflict of interest: C. M. Mellis has consultant arrangements with Merck Sharp & Dohme, Altana Pharma. The rest of the authors have declared that they have no conflict of interest.
PII: S0091-6749(06)00853-0
doi:10.1016/j.jaci.2006.04.004
© 2006 American Academy of Allergy, Asthma and Immunology. Published by Elsevier Inc. All rights reserved.
Volume 118, Issue 1 , Pages 53-61, July 2006
